Abstract
Rising rates of antibiotic resistance in uropathogenic bacteria compromise patient outcomes and prolong hospital stays. Consequently, new strategies are needed to prevent and control the spread of antibiotic resistance in uropathogenic bacteria. Over the past two decades, sizeable clinical efforts and research advances have changed urinary tract infection (UTI) treatment and prevention strategies to conserve antibiotic use. The emergence of antimicrobial stewardship, policies from national societies, and the development of new antimicrobials have shaped modern UTI practices. Future UTI management practices could be driven by the evolution of antimicrobial stewardship, improved and readily available diagnostics, and an improved understanding of how the microbiome affects UTI. Forthcoming UTI treatment and prevention strategies could employ novel bactericidal compounds, combinations of new and classic antimicrobials that enhance bacterial killing, medications that prevent bacterial attachment to uroepithelial cells, repurposing drugs, and vaccines to curtail the rising rates of antibiotic resistance in uropathogenic bacteria and improve outcomes in people with UTI.
Key points
-
Uropathogenic Escherichia coli is the most common cause of urinary tract infections (UTIs), but up to 90% of E. coli strains worldwide are resistant to at least one antibiotic.
-
Global, regional and community programmes educating clinicians on the current states of antibiotic use and resistance, monitoring or guiding antibiotic use, expanding pathogen testing, and promoting vaccination could reduce the prevalence of antibiotic resistance in uropathogenic bacteria.
-
Antibiotic and diagnostic stewardship programmes have benefited UTI management by reducing antibiotic use, improving patient outcomes, minimizing health-care costs and decreasing the incidence of antibiotic-resistant uropathogens.
-
Translational research efforts are leading to the development of nanoparticles, antimicrobial peptides and small molecules as promising antibiotic-conserving therapies for UTIs.
-
Diverse and healthy gastrointestinal and genitourinary microbiomes might prevent UTI recurrence and identifying avenues to prevent their dysbiosis could reduce antibiotic use.
Similar content being viewed by others
References
Foxman, B. The epidemiology of urinary tract infection. Nat. Rev. Urol. 7, 653–660 (2010).
Foxman, B., Barlow, R., D’Arcy, H., Gillespie, B. & Sobel, J. D. Urinary tract infection: self-reported incidence and associated costs. Ann. Epidemiol. 10, 509–515 (2000).
Al Lawati, H., Blair, B. M. & Larnard, J. Urinary tract infections: core curriculum 2024. Am. J. Kidney Dis. 83, 90–100 (2023).
Johnson, J. R. & Russo, T. A. Acute pyelonephritis in adults. N. Engl. J. Med. 378, 48–59 (2018).
Schwartz, L., de Dios Ruiz-Rosado, J., Stonebrook, E., Becknell, B. & Spencer, J. D. Uropathogen and host responses in pyelonephritis. Nat. Rev. Nephrol. 19, 658–671 (2023).
Foxman, B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. 113, 5S–13S (2002).
Dolk, F. C. K., Pouwels, K. B., Smith, D. R. M., Robotham, J. V. & Smieszek, T. Antibiotics in primary care in England: which antibiotics are prescribed and for which conditions? J. Antimicrob. Chemother. 73, ii2–ii10 (2018).
Goebel, M. C., Trautner, B. W. & Grigoryan, L. The five Ds of outpatient antibiotic stewardship for urinary tract infections. Clin. Microbiol. Rev. 34, e0000320 (2021).
Antimicrobial Resistance Collaborators. The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis. Lancet Reg. Health Am. 25, 100561 (2023).
World Health Organization. Antimicrobial resistance. WHO https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (2023).
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629–655 (2022).
Centers for Disease Control. Antibiotic resistance threats in the United States, 2019. CDC https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf (2019).
Nelson, R. E. et al. National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clin. Infect. Dis. 72, S17–S26 (2021).
Jonas, O. B. et al. Drug-resistant infections: a threat to our economic future. Vol. 2: Final report (English). http://documents.worldbank.org/curated/en/323311493396993758/final-report (World Bank Group, 2017) .
Poolman, J. T. & Wacker, M. Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. J. Infect. Dis. 213, 6–13 (2016).
Kaper, J. B., Nataro, J. P. & Mobley, H. L. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2, 123–140 (2004).
Zowawi, H. M. et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat. Rev. Urol. 12, 570–584 (2015).
Kot, B. Antibiotic resistance among uropathogenic Escherichia coli. Pol. J. Microbiol. 68, 403–415 (2019).
Wang, T. Z., Kodiyanplakkal, R. P. L. & Calfee, D. P. Antimicrobial resistance in nephrology. Nat. Rev. Nephrol. 15, 463–481 (2019).
MacFadden, D. R. et al. A platform for monitoring regional antimicrobial resistance, using online data sources: ResistanceOpen. J. Infect. Dis. 214, S393–S398 (2016).
Oldenkamp, R., Schultsz, C., Mancini, E. & Cappuccio, A. Filling the gaps in the global prevalence map of clinical antimicrobial resistance. Proc. Natl Acad. Sci. USA 118, 2013515118 (2021).
OneHealthTrust. ResistanceMap: Antibiotic resistance. 2024. ResistanceMap https://resistancemap.onehealthtrust.org/AntibioticResistance.php (2024).
Gupta, K. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 52, e103–e120 (2011).
Anger, J. T. et al. Updates to recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J. Urol. 208, 536–541 (2022).
Roberts, K. B. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics 128, 595–610 (2011).
Mori, R., Lakhanpaul, M. & Verrier-Jones, K. Diagnosis and management of urinary tract infection in children: summary of NICE guidance. BMJ 335, 395–397 (2007).
Tamma, P. D. et al. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciad428 (2023).
Naber, K. G., Bonkat, G. & Wagenlehner, F. M. E. The EAU and AUA/CUA/SUFU guidelines on recurrent urinary tract infections: what is the difference? Eur. Urol. 78, 645–646 (2020).
Ansari, M. S., Shekar, P. A., Singh, C. & Joshi, S. S. The Urological Society of India guidelines for the management of pediatric urinary tract infection (executive summary). Indian. J. Urol. 37, 10–12 (2021).
Hamasuna, R. et al. The JAID/JSC guidelines to Clinical Management of Infectious Disease 2017 concerning male urethritis and related disorders. J. Infect. Chemother. 27, 546–554 (2021).
Haddad, J. M. et al. Latin American consensus on uncomplicated recurrent urinary tract infection – 2018. Int. Urogynecol. J. 31, 35–44 (2020).
Kang, C. I. et al. Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections. Infect. Chemother. 50, 67–100 (2018).
Selekman, R. E., Allen, I. E. & Copp, H. L. Determinants of practice patterns in pediatric UTI management. J. Pediatr. Urol. 12, 308.e1–308.e6 (2016).
Langner, J. L., Chiang, K. F. & Stafford, R. S. Current prescribing practices and guideline concordance for the treatment of uncomplicated urinary tract infections in women. Am. J. Obstet. Gynecol. 225, 272.e1–272.e11 (2021).
Kikuchi, J. Y., Banaag, A. & Koehlmoos, T. P. Antibiotic prescribing patterns and guideline concordance for uncomplicated urinary tract infections among adult women in the US military health system. JAMA Netw. Open. 5, e2225730 (2022).
Alrosan, S. et al. An audit to reevaluate the adherence to the guidelines in patients with urinary tract infection at the Al-karak Hospital in Jordan. Cureus 15, e39509 (2023).
Lugtenberg, M., Burgers, J. S., Zegers-van Schaick, J. M. & Westert, G. P. Guidelines on uncomplicated urinary tract infections are difficult to follow: perceived barriers and suggested interventions. BMC Fam. Pract. 11, 51 (2010).
Markowitz, M. A. et al. Lack of uniformity among United States recommendations for diagnosis and management of acute, uncomplicated cystitis. Int. Urogynecol J. 30, 1187–1194 (2019).
Christiaens, T., De Backer, D., Burgers, J. & Baerheim, A. Guidelines, evidence, and cultural factors. Scand. J. Prim. Health Care 22, 141–145 (2004).
Zatorski, C. et al. A single center observational study on emergency department clinician non-adherence to clinical practice guidelines for treatment of uncomplicated urinary tract infections. BMC Infect. Dis. 16, 638 (2016).
Barlam, T. F. et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin. Infect. Dis. 62, e51–e77 (2016).
Nathwani, D. et al. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. Antimicrob. Resist. Infect. Control. 8, 35 (2019).
Zay Ya, K., Win, P. T. N., Bielicki, J., Lambiris, M. & Fink, G. Association between antimicrobial stewardship programs and antibiotic use globally: a systematic review and meta-analysis. JAMA Netw. Open. 6, e2253806 (2023).
Daley, M. F., Arnold Rehring, S. M., Glenn, K. A., Reifler, L. M. & Steiner, J. F. Improving antibiotic prescribing for pediatric urinary tract infections in outpatient settings. Pediatrics 145, e20192503 (2020).
Grigoryan, L. et al. Analysis of an antibiotic stewardship program for asymptomatic bacteriuria in the Veterans Affairs health care system. JAMA Netw. Open. 5, e2222530 (2022).
Jorgensen, S. C. J. et al. Leveraging antimicrobial stewardship in the emergency department to improve the quality of urinary tract infection management and outcomes. Open. Forum Infect. Dis. 5, ofy101 (2018).
Jover-Saenz, A. et al. Impact of a primary care antimicrobial stewardship program on bacterial resistance control and ecological imprint in urinary tract infections. Antibiotics (Basel) 11, 1776 (2022).
Landry, E., Sulz, L., Bell, A., Rathgeber, L. & Balogh, H. Urinary tract infections: leading initiatives in selecting empiric outpatient treatment (UTILISE). Can. J. Hosp. Pharm. 67, 116–125 (2014).
Nace, D. A. et al. A multifaceted antimicrobial stewardship program for the treatment of uncomplicated cystitis in nursing home residents. JAMA Intern. Med. 180, 944–951 (2020).
Percival, K. M. et al. Impact of an antimicrobial stewardship intervention on urinary tract infection treatment in the ED. Am. J. Emerg. Med. 33, 1129–1133 (2015).
Hartman, E. A. R. et al. Effect of a multifaceted antibiotic stewardship intervention to improve antibiotic prescribing for suspected urinary tract infections in frail older adults (ImpresU): pragmatic cluster randomised controlled trial in four European countries. BMJ 380, e072319 (2023).
Abbo, L. M. & Hooton, T. M. Antimicrobial stewardship and urinary tract infections. Antibiotics 3, 174–192 (2014).
US Preventive Services Task Force Screening for asymptomatic bacteriuria in adults: US Preventive Services Task Force recommendation statement. JAMA 322, 1188–1194 (2019).
Wiley, Z., Jacob, J. T. & Burd, E. M. Targeting asymptomatic bacteriuria in antimicrobial stewardship: the role of the microbiology laboratory. J. Clin. Microbiol. 58, e00518-18 (2020).
Nicolle, L. E. et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 68, e83–e110 (2019).
Koves, B. et al. Benefits and harms of treatment of asymptomatic bacteriuria: a systematic review and meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. Eur. Urol. 72, 865–868 (2017).
Chambers, A. et al. Virtual learning collaboratives to improve urine culturing and antibiotic prescribing in long-term care: controlled before-and-after study. BMJ Qual. Saf. 31, 94–104 (2022).
Claeys, K. C. & Johnson, M. D. Leveraging diagnostic stewardship within antimicrobial stewardship programmes. Drugs Context 12, 2022-9-5 (2023).
Claeys, K. C. et al. Optimal urine culture diagnostic stewardship practice – results from an expert modified-Delphi procedure. Clin. Infect. Dis. 75, 382–389 (2022).
Patel, R. et al. Envisioning future urinary tract infection diagnostics. Clin. Infect. Dis. 74, 1284–1292 (2022).
Werneburg, G. T. & Rhoads, D. D. Diagnostic stewardship for urinary tract infection: a snapshot of the expert guidance. Cleve Clin. J. Med. 89, 581–587 (2022).
Davenport, M. et al. New and developing diagnostic technologies for urinary tract infections. Nat. Rev. Urol. 14, 296–310 (2017).
Kazi, B. A. et al. Performance characteristics of urinalyses for the diagnosis of pediatric urinary tract infection. Am. J. Emerg. Med. 31, 1405–1407 (2013).
Alidjanov, J. F. et al. New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: Acute Cystitis Symptom Score. Urol. Int. 92, 230–236 (2014).
Alidjanov, J. F. et al. Acute Cystitis Symptom Score questionnaire for measuring patient-reported outcomes in women with acute uncomplicated cystitis: clinical validation as part of a phase III trial comparing antibiotic and nonantibiotic therapy. Investig. Clin. Urol. 61, 498–507 (2020).
Piontek, K. et al. Patient-reported outcome measures for uncomplicated urinary tract infections in women: a systematic review. Qual. Life Res. 32, 2137–2153 (2023).
Wagenlehner, F. M., Abramov-Sommariva, D., Holler, M., Steindl, H. & Naber, K. G. Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (fosfomycin trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre, non-inferiority phase III trial. Urol. Int. 101, 327–336 (2018).
Abbasi, A. et al. Discriminatory precision of neutrophil gelatinase-associated lipocalin in detection of urinary tract infection in children: a systematic review and meta-analysis. Arch. Acad. Emerg. Med. 8, e56 (2020).
Forster, C. S., Lubell, T. R., Dayan, P. S. & Shaikh, N. Accuracy of NGAL as a biomarker for urinary tract infection in young febrile children: an individual patient data meta-analysis. J. Pediatr. 258, 113394 (2023).
Hosseini, M. et al. The value of interleukin levels in the diagnosis of febrile urinary tract infections in children and adolescents; a systematic review and meta-analysis. J. Pediatr. Urol. 18, 211–223 (2022).
Nanda, N. & Juthani-Mehta, M. Novel biomarkers for the diagnosis of urinary tract infection – a systematic review. Biomark. Insights 4, 111–121 (2009).
Shaikh, K., Rajakumar, V., Osio, V. A. & Shaikh, N. Neutrophil gelatinase-associated lipocalin for urinary tract infection and pyelonephritis: a systematic review. Pediatr. Nephrol. 36, 1481–1487 (2021).
Morris, S. R. et al. Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study. Lancet Infect. Dis. 21, 668–676 (2021).
Almas, S. et al. Advantage of precision metagenomics for urinary tract infection diagnostics. Front. Cell Infect. Microbiol. 13, 1221289 (2023).
Price, T. K. et al. The clinical urine culture: enhanced techniques improve detection of clinically relevant microorganisms. J. Clin. Microbiol. 54, 1216–1222 (2016).
Pearce, M. M. et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio 5, e01283-14 (2014).
Sihra, N., Goodman, A., Zakri, R., Sahai, A. & Malde, S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat. Rev. Urol. 15, 750–776 (2018).
Ching, C. B. Non-antibiotic approaches to preventing pediatric UTIs: a role for D-mannose, cranberry, and probiotics? Curr. Urol. Rep. 23, 113–127 (2022).
Harding, C. et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ 376, e068229 (2022).
Lehár, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659–666 (2009).
Greve, J. M. & Cowan, J. A. Tackling antimicrobial stewardship through synergy and antimicrobial peptides. RSC Med. Chem. 13, 511–521 (2022).
Meyer, C. T. et al. Quantifying drug combination synergy along potency and efficacy axes. Cell Syst. 8, 97–108.e16 (2019).
Guo, J. et al. Effect of three different amino acids plus gentamicin against methicillin-resistant Staphylococcus aureus. Infect. Drug. Resist. 16, 4741–4754 (2023).
Coates, A. R. M., Hu, Y., Holt, J. & Yeh, P. Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction. Expert. Rev. Anti Infect. Ther. 18, 5–15 (2020).
Gómara, M. & Ramón-García, S. The FICI paradigm: correcting flaws in antimicrobial in vitro synergy screens at their inception. Biochem. Pharmacol. 163, 299–307 (2019).
Baym, M., Stone, L. K. & Kishony, R. Multidrug evolutionary strategies to reverse antibiotic resistance. Science 351, aad3292 (2016).
Hooton, T. M. & Samadpour, M. Is acute uncomplicated urinary tract infection a foodborne illness, and are animals the source? Clin. Infect. Dis. 40, 258–259 (2005).
Masters, P. A., O’Bryan, T. A., Zurlo, J., Miller, D. Q. & Joshi, N. Trimethoprim-sulfamethoxazole revisited. Arch. Intern. Med. 163, 402–410 (2003).
Reyes, S., Abdelraouf, K. & Nicolau, D. P. In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model. J. Antimicrob. Chemother. 75, 2197–2205 (2020).
Mavridou, E. et al. Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model. Antimicrob. Agents Chemother. 59, 790–795 (2015).
Heo, Y. A. Imipenem/cilastatin/relebactam: a review in gram-negative bacterial infections. Drugs 81, 377–388 (2021).
Doshi, P. Did the FDA break its own rules in approving the antibiotic Recarbrio? BMJ 381, 1048 (2023).
Moya, B., Zamorano, L., Juan, C., Ge, Y. & Oliver, A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54, 3933–3937 (2010).
Cluck, D., Lewis, P., Stayer, B., Spivey, J. & Moorman, J. Ceftolozane-tazobactam: a new-generation cephalosporin. Am. J. Health Syst. Pharm. 72, 2135–2146 (2015).
Lopez Montesinos, I., Montero, M., Sorli, L. & Horcajada, J. P. Ceftolozane-tazobactam: when, how and why using it? Rev. Esp. Quimioter. 34, 35–37 (2021).
Wagenlehner, F. M., Umeh, O., Steenbergen, J., Yuan, G. & Darouiche, R. O. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385, 1949–1956 (2015).
Stalenhoef, J. E. et al. Intravesical gentamicin treatment for recurrent urinary tract infections caused by multidrug resistant bacteria. J. Urol. 201, 549–555 (2019).
Morris, C. J., Rohn, J. L., Glickman, S. & Mansfield, K. J. Effective treatments of UTI – is intravesical therapy the future? Pathogens 12, 417 (2023).
Pietropaolo, A., Jones, P., Moors, M., Birch, B. & Somani, B. K. Use and effectiveness of antimicrobial intravesical treatment for prophylaxis and treatment of recurrent urinary tract infections (UTIs): a systematic review. Curr. Urol. Rep. 19, 78 (2018).
Reddy, M. & Zimmern, P. E. Efficacy of antimicrobial intravesical treatment for uncomplicated recurrent urinary tract infections: a systematic review. Int. Urogynecol J. 33, 1125–1143 (2022).
Ong, A., Pietropaolo, A., Brown, G. & Somani, B. K. Are intravesical aminoglycosides the new gold standard in the management of refractory urinary tract infection: a systematic review of literature. J. Clin. Med. 11, 5703 (2022).
Marei, M. M., Jackson, R. & Keene, D. J. B. Intravesical gentamicin instillation for the treatment and prevention of urinary tract infections in complex paediatric urology patients: evidence for safety and efficacy. J. Pediatr. Urol. 17, 65.e1–65.e11 (2021).
Horsley, H. et al. Ultrasound-activated microbubbles as a novel intracellular drug delivery system for urinary tract infection. J. Control. Rel. 301, 166–175 (2019).
Hsu, C. C., Chuang, Y. C. & Chancellor, M. B. Intravesical drug delivery for dysfunctional bladder. Int. J. Urol. 20, 552–562 (2013).
Barthelmes, J., Perera, G., Hombach, J., Dunnhaupt, S. & Bernkop-Schnurch, A. Development of a mucoadhesive nanoparticulate drug delivery system for a targeted drug release in the bladder. Int. J. Pharm. 416, 339–345 (2011).
Wierzbicka, A., Krakos, M., Wilczek, P. & Bociaga, D. A comprehensive review on hydrogel materials in urology: problems, methods, and new opportunities. J. Biomed. Mater. Res. B Appl. Biomater. 111, 730–756 (2023).
GuhaSarkar, S. & Banerjee, R. Intravesical drug delivery: challenges, current status, opportunities and novel strategies. J. Control. Rel. 148, 147–159 (2010).
Carpa, R., Remizovschi, A., Culda, C. A. & Butiuc-Keul, A. L. Inherent and composite hydrogels as promising materials to limit antimicrobial resistance. Gels 8, 70 (2022).
Palugan, L. et al. Intravesical drug delivery approaches for improved therapy of urinary bladder diseases. Int. J. Pharm. X 3, 100100 (2021).
Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug. Discov. 20, 101–124 (2021).
Qindeel, M., Barani, M., Rahdar, A., Arshad, R. & Cucchiarini, M. Nanomaterials for the diagnosis and treatment of urinary tract infections. Nanomaterials 11, 546 (2021).
Sanchez, S. V., Navarro, N., Catalan-Figueroa, J. & Morales, J. O. Nanoparticles as potential novel therapies for urinary tract infections. Front. Cell Infect. Microbiol. 11, 656496 (2021).
Lethongkam, S. et al. Eucalyptus-mediated synthesized silver nanoparticles-coated urinary catheter inhibits microbial migration and biofilm formation. Nanomaterials 12, 4059 (2022).
Rugaie, O. A. et al. Retardation of bacterial biofilm formation by coating urinary catheters with metal nanoparticle-stabilized polymers. Microorganisms 10, 1297 (2022).
Mittal, R. et al. Local drug delivery in the urinary tract: current challenges and opportunities. J. Drug. Target. 26, 658–669 (2018).
Erman, A. & Veranic, P. The use of polymer chitosan in intravesical treatment of urinary bladder cancer and infections. Polymers 10, 265 (2018).
Iyer, J. K. et al. Nanodiamonds facilitate killing of intracellular uropathogenic E. coli in an in vitro model of urinary tract infection pathogenesis. PLoS ONE 13, e0191020 (2018).
Khanal, M. et al. Inhibition of type 1 fimbriae-mediated Escherichia coli adhesion and biofilm formation by trimeric cluster thiomannosides conjugated to diamond nanoparticles. Nanoscale 7, 2325–2335 (2015).
Beranova, J. et al. Sensitivity of bacteria to diamond nanoparticles of various size differs in gram-positive and gram-negative cells. FEMS Microbiol. Lett. 351, 179–186 (2014).
Shreffler, J. W., Pullan, J. E., Dailey, K. M., Mallik, S. & Brooks, A. E. Overcoming hurdles in nanoparticle clinical translation: the influence of experimental design and surface modification. Int. J. Mol. Sci. 20, 6056 (2019).
Becknell, B., Schwaderer, A., Hains, D. S. & Spencer, J. D. Amplifying renal immunity: the role of antimicrobial peptides in pyelonephritis. Nat. Rev. Nephrol. 11, 642–655 (2015).
Jiang, Y., Chen, Y., Song, Z., Tan, Z. & Cheng, J. Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation. Adv. Drug. Deliv. Rev. 170, 261–280 (2021).
Lacerda Mariano, L. & Ingersoll, M. A. The immune response to infection in the bladder. Nat. Rev. Urol. 17, 439–458 (2020).
Kuhn, H. W., Hreha, T. N. & Hunstad, D. A. Immune defenses in the urinary tract. Trends Immunol. 44, 701–711 (2023).
Ali, A. S., Townes, C. L., Hall, J. & Pickard, R. S. Maintaining a sterile urinary tract: the role of antimicrobial peptides. J. Urol. 182, 21–28 (2009).
Dijksteel, G. S., Ulrich, M. M. W., Middelkoop, E. & Boekema, B. Review: lessons learned from clinical trials using antimicrobial peptides (AMPs). Front. Microbiol. 12, 616979 (2021).
Håversen, L. A. et al. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infect. Immun. 68, 5816–5823 (2000).
Canas, J. J. et al. Human neutrophil peptides 1-3 protect the murine urinary tract from uropathogenic Escherichia coli challenge. Proc. Natl Acad. Sci. USA 119, e2206515119 (2022).
Kai-Larsen, Y. et al. Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37. PLoS Pathog. 6, e1001010 (2010).
Ridyard, K. E. et al. Synergy between human peptide LL-37 and polymyxin B against planktonic and biofilm cells of Escherichia coli and Pseudomonas aeruginosa. Antibiotics 12, 389 (2023).
Tantisuwanno, C. et al. Synergism between rifampicin and cationic polyurethanes overcomes intrinsic resistance of Escherichia coli. Biomacromolecules 22, 2910–2920 (2021).
Souza, P. F. N. et al. Synthetic antimicrobial peptides: from choice of the best sequences to action mechanisms. Biochimie 175, 132–145 (2020).
Sechet, E., Telford, E., Bonamy, C., Sansonetti, P. J. & Sperandio, B. Natural molecules induce and synergize to boost expression of the human antimicrobial peptide β-defensin-3. Proc. Natl Acad. Sci. USA 115, E9869–E9878 (2018).
Schwartz, L. et al. Repurposing HDAC inhibitors to enhance ribonuclease 4 and 7 expression and reduce urinary tract infection. Proc. Natl Acad. Sci. USA 120, e2213363120 (2023).
Hertting, O. et al. Vitamin D induction of the human antimicrobial peptide cathelicidin in the urinary bladder. PLoS ONE 5, e15580 (2010).
Majhi, R. K. et al. Metformin strengthens uroepithelial immunity against E. coli infection. Sci. Rep. 11, 19263 (2021).
Luthje, P. et al. Estrogen supports urothelial defense mechanisms. Sci. Transl. Med. 5, 190ra180 (2013).
Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13, 269–284 (2015).
Cegelski, L. et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat. Chem. Biol. 5, 913–919 (2009).
Pinkner, J. S. et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl Acad. Sci. USA 103, 17897–17902 (2006).
Montes-Robledo, A., Baldiris-Avila, R. & Galindo, J. F. D-Mannoside FimH inhibitors as non-antibiotic alternatives for uropathogenic Escherichia coli. Antibiotics 10, 1072 (2021).
Mydock-McGrane, L. et al. Antivirulence C-mannosides as antibiotic-sparing, oral therapeutics for urinary tract infections. J. Med. Chem. 59, 9390–9408 (2016).
Totsika, M. et al. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J. Infect. Dis. 208, 921–928 (2013).
Klein, T. et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J. Med. Chem. 53, 8627–8641 (2010).
McLellan, L. K. et al. A host receptor enables type 1 pilus-mediated pathogenesis of Escherichia coli pyelonephritis. PLoS Pathog. 17, e1009314 (2021).
Cusumano, C. K. et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci. Transl. Med. 3, 109ra115 (2011).
Leitner, L. et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect. Dis. 21, 427–436 (2021).
Leitner, L. et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol. 17, 90 (2017).
Ujmajuridze, A. et al. Adapted bacteriophages for treating urinary tract infections. Front. Microbiol. 9, 1832 (2018).
Gu, Y. et al. Identification of novel bacteriophage vB_EcoP-EG1 with lytic activity against planktonic and biofilm forms of uropathogenic Escherichia coli. Appl. Microbiol. Biotechnol. 103, 315–326 (2019).
Pires, D. P., Melo, L., Vilas Boas, D., Sillankorva, S. & Azeredo, J. Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections. Curr. Opin. Microbiol. 39, 48–56 (2017).
Aziminia, N. et al. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 123, 753–768 (2019).
Loubet, P. et al. Alternative therapeutic options to antibiotics for the treatment of urinary tract infections. Front. Microbiol. 11, 1509 (2020).
Langermann, S. et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J. Infect. Dis. 181, 774–778 (2000).
Butler, D. et al. Immunomodulation therapy offers new molecular strategies to treat UTI. Nat. Rev. Urol. 19, 419–437 (2022).
Ambite, I. et al. Molecular basis of acute cystitis reveals susceptibility genes and immunotherapeutic targets. PLoS Pathog. 12, e1005848 (2016).
Butler, D. S. C. et al. Neuroepithelial control of mucosal inflammation in acute cystitis. Sci. Rep. 8, 11015 (2018).
Hannan, T. J. et al. Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis. EBioMedicine 1, 46–57 (2014).
Puthia, M. et al. IRF7 inhibition prevents destructive innate immunity – target for nonantibiotic therapy of bacterial infections. Sci. Transl. Med. 8, 336ra359 (2016).
Eichler, T. E. et al. Insulin and the phosphatidylinositol 3-kinase signaling pathway regulate ribonuclease 7 expression in the human urinary tract. Kidney Int. 90, 568–579 (2016).
Stapleton, A. E. The vaginal microbiota and urinary tract infection. Microbiol. Spectr. https://doi.org/10.1128/microbiolspec.UTI-0025-2016 (2016).
Perrotta, C., Aznar, M., Mejia, R., Albert, X. & Ng, C. W. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst. Rev. 2, CD005131 (2008).
Blakeman, P. J., Hilton, P. & Bulmer, J. N. Cellular proliferation in the female lower urinary tract with reference to oestrogen status. BJOG 108, 813–816 (2001).
Lüthje, P., Hirschberg, A. L. & Brauner, A. Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas 77, 32–36 (2014).
Jobin, K. et al. A high-salt diet compromises antibacterial neutrophil responses through hormonal perturbation. Sci. Transl. Med. 12, eaay3850 (2020).
Murtha, M. J. et al. Insulin receptor signaling regulates renal collecting duct and intercalated cell antibacterial defenses. J. Clin. Invest. 128, 5634–5646 (2018).
Brauner, H. et al. Markers of innate immune activity in patients with type 1 and type 2 diabetes mellitus and the effect of the anti-oxidant coenzyme Q10 on inflammatory activity. Clin. Exp. Immunol. 177, 478–482 (2014).
Mohanty, S. et al. Diabetes downregulates the antimicrobial peptide psoriasin and increases E. coli burden in the urinary bladder. Nat. Commun. 13, 4983 (2022).
Chassin, C. et al. Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin. J. Exp. Med. 204, 2837–2852 (2007).
Olson, P. D., Hruska, K. A. & Hunstad, D. A. Androgens enhance male urinary tract infection severity in a new model. J. Am. Soc. Nephrol. 27, 1625–1634 (2016).
Olson, P. D. et al. Androgen exposure potentiates formation of intratubular communities and renal abscesses by Escherichia coli. Kidney Int. 94, 502–513 (2018).
Hreha, T. N. et al. Androgen-influenced polarization of activin A-producing macrophages accompanies post-pyelonephritic renal scarring. Front. Immunol. 11, 1641 (2020).
Hreha, T. N. et al. TGFβ1 orchestrates renal fibrosis following Escherichia coli pyelonephritis. Physiol. Rep. 8, e14401 (2020).
Jones-Freeman, B. et al. The microbiome and host mucosal interactions in urinary tract diseases. Mucosal Immunol. 14, 779–792 (2021).
Neugent, M. L., Hulyalkar, N. V., Nguyen, V. H., Zimmern, P. E. & De Nisco, N. J. Advances in understanding the human urinary microbiome and its potential role in urinary tract infection. mBio 11, e00218-20 (2020).
Lewis, A. L. & Gilbert, N. M. Roles of the vagina and the vaginal microbiota in urinary tract infection: evidence from clinical correlations and experimental models. GMS Infect. Dis. 8, Doc02 (2020).
Magruder, M. et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat. Commun. 10, 5521 (2019).
Thomas-White, K. et al. Culturing of female bladder bacteria reveals an interconnected urogenital microbiota. Nat. Commun. 9, 1557 (2018).
Wolfe, A. J. et al. Evidence of uncultivated bacteria in the adult female bladder. J. Clin. Microbiol. 50, 1376–1383 (2012).
Thanert, R. et al. Comparative genomics of antibiotic-resistant uropathogens implicates three routes for recurrence of urinary tract infections. mBio 10, e01977-19 (2019).
Spaulding, C. N. et al. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist. Nature 546, 528–532 (2017).
Engelsöy, U., Svensson, M. A. & Demirel, I. Estradiol alters the virulence traits of uropathogenic Escherichia coli. Front. Microbiol. 12, 682626 (2021).
Worby, C. J. et al. Longitudinal multi-omics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in women. Nat. Microbiol. 7, 630–639 (2022).
Worby, C. J., Olson, B. S., Dodson, K. W., Earl, A. M. & Hultgren, S. J. Establishing the role of the gut microbiota in susceptibility to recurrent urinary tract infections. J. Clin. Invest. 132, e158497 (2022).
Paalanne, N. et al. Intestinal microbiome as a risk factor for urinary tract infections in children. Eur. J. Clin. Microbiol. Infect. Dis. 37, 1881–1891 (2018).
Antonio, M. A., Hawes, S. E. & Hillier, S. L. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J. Infect. Dis. 180, 1950–1956 (1999).
Chen, C. et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat. Commun. 8, 875 (2017).
Liu, Y. & Li, Z. Vaginal pH value can affect the susceptibility to human papillomavirus infection. BMC Infect. Dis. 24, 176 (2024).
Hooton, T. M., Fihn, S. D., Johnson, C., Roberts, P. L. & Stamm, W. E. Association between bacterial vaginosis and acute cystitis in women using diaphragms. Arch. Intern. Med. 149, 1932–1936 (1989).
Sumati, A. H. & Saritha, N. K. Association of urinary tract infection in women with bacterial vaginosis. J. Glob. Infect. Dis. 1, 151–152 (2009).
Joyce, C., Halverson, T., Gonzalez, C., Brubaker, L. & Wolfe, A. J. The urobiomes of adult women with various lower urinary tract symptoms status differ: a re-analysis. Front. Cell Infect. Microbiol. 12, 860408 (2022).
Kawalec, A. & Zwolinska, D. Emerging role of microbiome in the prevention of urinary tract infections in children. Int. J. Mol. Sci. 23, 870 (2022).
Song, C. H. et al. Lactobacillus crispatus limits bladder uropathogenic E. coli infection by triggering a host type I interferon response. Proc. Natl Acad. Sci. USA 119, e2117904119 (2022).
Nelson, D. E. et al. Bacterial communities of the coronal sulcus and distal urethra of adolescent males. PLoS ONE 7, e36298 (2012).
Dong, Q. et al. The microbial communities in male first catch urine are highly similar to those in paired urethral swab specimens. PLoS ONE 6, e19709 (2011).
Price, L. B. et al. The effects of circumcision on the penis microbiome. PLoS ONE 5, e8422 (2010).
Cole, E., Shaikh, N. & Forster, C. S. The pediatric urobiome in genitourinary conditions: a narrative review. Pediatr. Nephrol. 37, 1443–1452 (2022).
Gerber, D., Forster, C. S. & Hsieh, M. The role of the genitourinary microbiome in pediatric urology: a review. Curr. Urol. Rep. 19, 13 (2018).
Tuddenham, S. et al. Lactobacillus-dominance and rapid stabilization of vaginal microbiota in combined oral contraceptive pill users examined through a longitudinal cohort study with frequent vaginal sampling over two years. EBioMedicine 87, 104407 (2023).
Neugent, M. L. et al. Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome. Cell Rep. Med. 3, 100753 (2022).
Cauci, S. et al. Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women. J. Clin. Microbiol. 40, 2147–2152 (2002).
Raz, R. & Stamm, W. E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N. Engl. J. Med. 329, 753–756 (1993).
Wu, F. et al. Improvement of vaginal probiotics Lactobacillus crispatus on intrauterine adhesion in mice model and in clinical practice. BMC Microbiol. 23, 78 (2023).
Stapleton, A. E. et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin. Infect. Dis. 52, 1212–1217 (2011).
Macklaim, J. M., Clemente, J. C., Knight, R., Gloor, G. B. & Reid, G. Changes in vaginal microbiota following antimicrobial and probiotic therapy. Microb. Ecol. Health Dis. 26, 27799 (2015).
Shoureshi, P. S., Niino, C. & Eilber, K. S. Can vaginal lactobacillus suppositories help reduce urinary tract infections? Int. Urogynecol. J. 34, 2713–2718 (2023).
Elvers, K. T. et al. Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review. BMJ Open. 10, e035677 (2020).
Zimmermann, P. & Curtis, N. The effect of antibiotics on the composition of the intestinal microbiota – a systematic review. J. Infect. 79, 471–489 (2019).
Gottschick, C. et al. The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. Microbiome 5, 99 (2017).
Edlund, C. et al. The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden. Lancet Infect. Dis. 22, 390–400 (2022).
Mayer, B. T. et al. Rapid and profound shifts in the vaginal microbiota following antibiotic treatment for bacterial vaginosis. J. Infect. Dis. 212, 793–802 (2015).
Rani, A. et al. Urinary microbiome of kidney transplant patients reveals dysbiosis with potential for antibiotic resistance. Transl. Res. 181, 59–70 (2017).
Tariq, R., Tosh, P. K., Pardi, D. S. & Khanna, S. Reduction in urinary tract infections in patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection. Eur. J. Clin. Microbiol. Infect. Dis. 42, 1037–1041 (2023).
Wood, N., Propst, K., Yao, M. & Ferrando, C. A. Fecal microbiota transfer for Clostridium difficile infection and its effects on recurrent urinary tract infection. Urogynecology 29, 814–826 (2023).
Tuniyazi, M. & Zhang, N. Possible therapeutic mechanisms and future perspectives of vaginal microbiota transplantation. Microorganisms 11, 1427 (2023).
US National Library of Medicine. ClinicalTrials.gov ClinicalTrials.gov/show/NCT06045832 (2023).
US National Library of Medicine. ClinicalTrials.gov ClinicalTrials.gov/show/NCT05603598 (2022).
US National Library of Medicine. ClinicalTrials.gov ClinicalTrials.gov/show/NCT05530252 (2022).
US National Library of Medicine. ClinicalTrials.gov ClinicalTrials.gov/show/NCT05340790 (2023).
US National Library of Medicine. ClinicalTrials.gov ClinicalTrials.gov/show/NCT05137314 (2022).
Chinese Clinical Trial Registry. ChiCTR www.chictr.org.cn/showprojEN.html?proj=207110 (2024).
Chinese Clinical Trial Registry. ChiCTR www.chictr.org.cn/showprojEN.html?proj=195731 (2023).
ISRCTN Registry. ISRCTN www.isrctn.com/ISRCTN38383374 (2016).
ISRCTN Registry. ISRCTN www.isrctn.com/ISRCTN12149720 (2023).
US National Library of Medicine. ClinicalTrials.gov ClinicalTrials.gov/show/NCT02225366 (2021).
University hospital Medical Information Network. UMIN center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014826 (2019).
Cochrane Library. A phase-III clinical trials of xylentra versus silver sulfadiazine for efficacy and safety in burn wound patients. Cochrane Library www.cochranelibrary.com/central/doi/10.1002/central/CN-01870388/full (2019).
Acknowledgements
C.B.C. and J.D.S. disclose support for publication of this work from the National Institutes of Health (NIDDK): K08 DK122119, R01 DK115737, DK114035 and DK128088.
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of the article.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Urology thanks Florian Wagenlehner, Zafer Tandogduand the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
Acute Cystitis Symptom Score: https://www.acss.world/
ResistanceMap: https://resistancemap.onehealthtrust.org/AntibioticResistance.php
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Simoni, A., Schwartz, L., Junquera, G.Y. et al. Current and emerging strategies to curb antibiotic-resistant urinary tract infections. Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00877-9
Accepted:
Published:
DOI: https://doi.org/10.1038/s41585-024-00877-9
- Springer Nature Limited